ClinicalTrials.gg
CompletedNCT01135914RESPONDUpdated Oct 23, 2014Results posted

Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)

A Phase 3 interventional study of ranibizumab and Laser in Diabetic Macular Edema, sponsored by Novartis Pharmaceuticals. Completed at 20 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
241
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 26 studies testing ranibizumab in Vision Disorders — none open to participants now, none under way, none of them phase 3. Ranibizumab · Vision Disorders.

Enrollment
11th of 26
241 · median 178
Started
2010
with 1 other
Phase 3
14 of 26
none open now
Registered
6th of 26
by date
Lead sponsor
20 of 26
Novartis Pharmaceuticals

Among the 26 studies testing ranibizumab in Vision Disorders, this one is the 11th largest by enrollment, is one of 2 that started in 2010, is one of 14 in phase 3, and was the 6th registered.

Vision Disorders

361 studies on the registry are indexed under Vision Disorders; 85 are open to participants now.

Browse Vision Disorders studies →

Open to participants now

None of the 26 studies testing ranibizumab in Vision Disorders is open now. The open studies under Vision Disorders, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Vision Disorders studies recruiting now, 21 (46%) set no upper age limit and 16 (35%) stop at 75 or younger; 18 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing ranibizumab in Vision Disorders as a file.
02

Study summary

To evaluate, specifically within the Canadian medical environment, the efficacy, safety and cost-efficacy of ranibizumab administered either as combination therapy (ranibizumab plus laser photocoagulation), or as monotherapy in comparison with the current standard of care (laser photocoagulation monotherapy), in patients with visual impairment due to DME.

03

Conditions studied

  • Diabetic Macular Edema

Keywords

  • DME
  • visual impairment
  • diabetes
  • macular edema
  • diabetic macular edema
  • ranibizumab
  • laser
  • photocoagulation
  • retinopathy
  • retina
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stable Type 1 or Type 2 diabetes mellitus
  • Visual impairment due to focal or diffuse DME in at least one eye

Exclusion criteria

Exclusion Criteria:

  • Active conditions in the study eye that could prevent the improvement of visual acuity on study treatment
  • Active eye infection or inflammation
  • History of stroke, renal failure or uncontrolled hypertension

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
241 participants (actual)

Study arms

  • Experimental
    Combination Therapy

    Participants received ranibizumab intravitreal injection and laser photocoagulation treatments

    Drug: ranibizumab · Procedure: Laser

  • Experimental
    Ranibizumab Monotherapy

    Participants received ranibizumab intravitreal injection therapy only

    Drug: ranibizumab

  • Active comparator
    Laser Monotherapy

    Participants received Laser photocoagulation therapy only

    Procedure: Laser

Interventions

  • Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.

  • ProcedureLaser

    Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Best Corrected Visual Acuity- (BCVA) at Month 12

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS) is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement.

    Time frame: Baseline and 12 months

Secondary outcomes

  1. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Months 3,6 and 9

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS)is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement.

    Time frame: Baseline, 3, 6 and 9 months

  2. Change From Baseline in Central Retinal Thickness (CRT) at Months 3,6,9 and 12

    OCT is a diagnostic imaging technique using low-coherence interferometry to produce cross-sectional tomograms of the posterior segment eye structures. OCT was performed prior to study treatment to assess CRT, presence of fluid in the macula (intra-retinal cyst or fluid) and evaluation of image to monitor disease progression/treatment effect and to determine the need to stop/re-initiate ranibizumab treatment

    Time frame: Baseline, 3, 6, 9 and 12 months

  3. Percentage of Patients Achieving a Gain of 15-letters or More (3-lines) in BCVA From Baseline

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS) is 0 to 100 letters. A higher percent of patients achieving a gain of ≥15 letters BCVA indicates a better response.

    Time frame: Baseline, 3, 6, 9 and 12 months

  4. Percentage of Patients Achieving Gain of Letters From Baseline in BCVA

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS) is 0 to 100 letters. A gain of 5,10,15 or more BCVA letters from baseline indicates improvement.

    Time frame: 12 months

  5. National Eye Institute Visual Functioning Questionnaire - 25 (VFQ-25) Composite Score at Month 12

    The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure the influence of visual disability and visual symptoms on general health domains. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. For each question, the patient was asked to rate their condition on a scale of 1-5 or 1-6, where a low number reflects a better outcome. A composite score for a patient is calculated by aggregating and averaging the scores from the 11 sub-scales (excluding general health sub-scale), and an algorithm is apply to give equal weight to each sub-scale. Sub-scales and composite scores are calculated by converting the response from questionnaires into a 0-100 scale, with 0 as the worst possible outcome and 100 as the best. Missing data was not imputed

    Time frame: 12 month

  6. EuroQoL (EQ-5D) Utility Score at Month 12

    The Euro Quality of Life Questionnaire (EQ-5D) standardized instrument was utilized to measure health outcomes related to 5 dimensions, namely: mobility, self-care, usual activities, pain-discomfort, and anxiety/depression. The possible range for each dimension was 1 to 3, where 1="no problems", 2="some problems" and 3="extreme problems". Missing values were not imputed. Using the scoring algorithm derived from the Canadian value sets (Bansback et al., 2012), a utility score for a patient was calculated based on the EQ-5D responses for a given time-point at which the questionnaire was presented to the patient. This mean EQ-5D utility score ranged between 0 (worst health) to 1 (perfect health).

    Time frame: 12 month

  7. Time Trade-Off Questionnaire - 25 (TTO) Composite Score at Month 12

    (TTO) questionnaire was used to help determine the patients' health utility. Reported health utility represents the patients' quality of life at the current health state, and is a cardinal value that ranges from 0 (worst possible health or death) to 1 (best possible health). In this questionnaire, patients were first asked to estimate their remaining life expectancy. Second, the patients were presented with a hypothetical situation where a technology existed that could permanently return their vision to normal. This technology would always work, but would decrease their length of survival. Patients were then asked how much of their remaining life expectancy, if any, they would be willing to trade in return for use of the technology and thus for normal vision. The principle of this measure is that if patients were content with their current vision status (i.e., have a utility value of 1.0), they would not want to trade any of their remaining life years to improve their vision.

    Time frame: 12 month

07

Results

Posted Oct 23, 2014

Participant flow

A total of 239 patients were enrolled in the study. An additional 2 patients were enrolled but were removed from the database because consent was not signed in accordance with GCP principles."

Participant flow — Overall Study
MilestoneCombination TherapyRanibizumab MonotherapyLaser Monotherapy
Started788081
Intent to treat (itt) population737572
Safety population737574
Completed747559
Not completed4522
Withdrew: Withdrawal by subject136
Withdrew: Lost to follow-up101
Withdrew: Protocol violation003
Withdrew: Lack of efficacy2110
Withdrew: Adverse event012

Outcome measures

PrimaryMean Change From Baseline in Best Corrected Visual Acuity- (BCVA) at Month 12

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS) is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement.

Time frame:
Baseline and 12 months
Reported as:
Mean · Letters
Mean Change From Baseline in Best Corrected Visual Acuity- (BCVA) at Month 12
LettersCombination TherapyRanibizumab MonotherapyLaser Monotherapy
Mean Change From Baseline in Best Corrected Visual Acuity- (BCVA) at Month 128.2 ± 9.208.9 ± 7.780.3 ± 12.47
SecondaryMean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Months 3,6 and 9

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS)is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement.

Time frame:
Baseline, 3, 6 and 9 months
Reported as:
Mean · Letters
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Months 3,6 and 9
LettersCombination TherapyRanibizumab MonotherapyLaser Monotherapy
Month 3 (n=71, 75, 69)3.7 ± 10.715.3 ± 7.581.4 ± 6.55
Month 6 (n= 70, 72, 65)5.6 ± 8.457.1 ± 7.740.9 ± 7.23
Month 9 (n=69, 71, 59)7.1 ± 7.926.9 ± 12.45-0.2 ± 10.71
SecondaryChange From Baseline in Central Retinal Thickness (CRT) at Months 3,6,9 and 12

OCT is a diagnostic imaging technique using low-coherence interferometry to produce cross-sectional tomograms of the posterior segment eye structures. OCT was performed prior to study treatment to assess CRT, presence of fluid in the macula (intra-retinal cyst or fluid) and evaluation of image to monitor disease progression/treatment effect and to determine the need to stop/re-initiate ranibizumab treatment

Time frame:
Baseline, 3, 6, 9 and 12 months
Reported as:
Mean · um
Change From Baseline in Central Retinal Thickness (CRT) at Months 3,6,9 and 12
umCombination TherapyRanibizumab MonotherapyLaser Monotherapy
Baseline422.1 ± 142.26448.5 ± 136.64458.0 ± 133.07
Month 3 (n=71,75, 69)-105.7 ± 127.74-108.9 ± 113.38-32.5 ± 114.15
Month 6 (n= 70,72,65)-114.2 ± 110.88-129.3 ± 116.50-64.4 ± 110.77
Month 9 (69,70,58)-138.1 ± 125.86-135.9 ± 140.90-85.8 ± 128.00
Month 12 (70,71,61)-152.2 ± 139.27-143.5 ± 143.95-107.1 ± 143.86
SecondaryPercentage of Patients Achieving a Gain of 15-letters or More (3-lines) in BCVA From Baseline

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS) is 0 to 100 letters. A higher percent of patients achieving a gain of ≥15 letters BCVA indicates a better response.

Time frame:
Baseline, 3, 6, 9 and 12 months
Reported as:
Number · Percentage of Patients
Percentage of Patients Achieving a Gain of 15-letters or More (3-lines) in BCVA From Baseline
Percentage of PatientsCombination TherapyRanibizumab MonotherapyLaser Monotherapy
Month 3 (n=71,75,69)8.59.32.9
Month 6 (n=70,72,65)11.413.91.5
Month 9 (69,71,59)13.021.10
Month 12 (70,71,62)24.321.16.5
SecondaryPercentage of Patients Achieving Gain of Letters From Baseline in BCVA

Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS) is 0 to 100 letters. A gain of 5,10,15 or more BCVA letters from baseline indicates improvement.

Time frame:
12 months
Reported as:
Number · Percentage of Patients
Percentage of Patients Achieving Gain of Letters From Baseline in BCVA
Percentage of PatientsCombination TherapyRanibizumab MonotherapyLaser Monotherapy
5 letter gain61.470.440.3
10 letter gain34.352.116.1
15 letter gain24.321.16.5
SecondaryNational Eye Institute Visual Functioning Questionnaire - 25 (VFQ-25) Composite Score at Month 12

The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure the influence of visual disability and visual symptoms on general health domains. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. For each question, the patient was asked to rate their condition on a scale of 1-5 or 1-6, where a low number reflects a better outcome. A composite score for a patient is calculated by aggregating and averaging the scores from the 11 sub-scales (excluding general health sub-scale), and an algorithm is apply to give equal weight to each sub-scale. Sub-scales and composite scores are calculated by converting the response from questionnaires into a 0-100 scale, with 0 as the worst possible outcome and 100 as the best. Missing data was not imputed

Time frame:
12 month
Reported as:
Mean · Units on a Scale
National Eye Institute Visual Functioning Questionnaire - 25 (VFQ-25) Composite Score at Month 12
Units on a ScaleCombination TherapyRanibizumab MonotherapyLaser Monotherapy
National Eye Institute Visual Functioning Questionnaire - 25 (VFQ-25) Composite Score at Month 1285.21 ± 12.7784.29 ± 11.7878.20 ± 17.27
SecondaryEuroQoL (EQ-5D) Utility Score at Month 12

The Euro Quality of Life Questionnaire (EQ-5D) standardized instrument was utilized to measure health outcomes related to 5 dimensions, namely: mobility, self-care, usual activities, pain-discomfort, and anxiety/depression. The possible range for each dimension was 1 to 3, where 1="no problems", 2="some problems" and 3="extreme problems". Missing values were not imputed. Using the scoring algorithm derived from the Canadian value sets (Bansback et al., 2012), a utility score for a patient was calculated based on the EQ-5D responses for a given time-point at which the questionnaire was presented to the patient. This mean EQ-5D utility score ranged between 0 (worst health) to 1 (perfect health).

Time frame:
12 month
Reported as:
Mean · Units on a scale
EuroQoL (EQ-5D) Utility Score at Month 12
Units on a scaleCombination TherapyRanibizumab MonotherapyLaser Monotherapy
EuroQoL (EQ-5D) Utility Score at Month 120.88 ± 0.150.88 ± 0.170.87 ± 0.17
SecondaryTime Trade-Off Questionnaire - 25 (TTO) Composite Score at Month 12

(TTO) questionnaire was used to help determine the patients' health utility. Reported health utility represents the patients' quality of life at the current health state, and is a cardinal value that ranges from 0 (worst possible health or death) to 1 (best possible health). In this questionnaire, patients were first asked to estimate their remaining life expectancy. Second, the patients were presented with a hypothetical situation where a technology existed that could permanently return their vision to normal. This technology would always work, but would decrease their length of survival. Patients were then asked how much of their remaining life expectancy, if any, they would be willing to trade in return for use of the technology and thus for normal vision. The principle of this measure is that if patients were content with their current vision status (i.e., have a utility value of 1.0), they would not want to trade any of their remaining life years to improve their vision.

Time frame:
12 month
Reported as:
Mean · Units on a scale
Time Trade-Off Questionnaire - 25 (TTO) Composite Score at Month 12
Units on a scaleCombination TherapyRanibizumab MonotherapyLaser Monotherapy
Time Trade-Off Questionnaire - 25 (TTO) Composite Score at Month 120.83 ± 0.280.78 ± 0.230.80 ± 0.24

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combination Therapy—9/73 (12.3%)26/73 (35.6%)
Ranibizumab Monotherapy—10/75 (13.3%)26/75 (34.7%)
Laser Monotherapy—5/74 (6.8%)17/74 (23%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventCombination TherapyRanibizumab MonotherapyLaser Monotherapy
Cardiac failure congestiveCardiac disorders0/730/752/74
Vitreous haemorrhage (Fellow eye)Eye disorders0/730/752/74
Vitreous haemorrhage (Study eye)Eye disorders0/730/752/74
CellulitisInfections and infestations0/732/750/74
Atrial fibrillationCardiac disorders1/730/750/74
Colitis ischaemicGastrointestinal disorders1/730/750/74
Intestinal obstructionGastrointestinal disorders1/730/750/74
HypothermiaGeneral disorders1/730/750/74
SarcoidosisImmune system disorders1/730/750/74
Diabetic foot infectionInfections and infestations1/730/750/74
Most frequent other events
Showing 10 of 14
Most frequent other events
EventCombination TherapyRanibizumab MonotherapyLaser Monotherapy
Intraocular pressure increased (Study eye)Investigations8/7310/750/74
Conjunctival haemorrhage (Study eye)Eye disorders9/736/751/74
NasopharyngitisInfections and infestations5/735/754/74
Neuropathy peripheralNervous system disorders5/731/750/74
HypertensionVascular disorders2/735/755/74
Cataract (Fellow eye)Eye disorders0/735/753/74
Cataract (Study eye)Eye disorders0/735/750/74
Eye irritation (Study eye)Eye disorders4/730/750/74
Vision blurred (Study eye)Eye disorders4/730/750/74
Vitreous haemorrhage (Fellow eye)Eye disorders4/732/751/74

Baseline characteristics

The Intent to Treat (ITT) population was defined as all patients receiving at least one dose of either study treatment for monotherapy treatment arms, or one of the two study treatments for the combination therapy arm, and having at least 1 post-baseline assessment. Patients from a center were excluded from ITT.

Age, Continuous
Age, Continuous(years)Combination TherapyRanibizumab MonotherapyLaser MonotherapyTotal
Mean60.8 ± 10.2161.5 ± 9.8662.8 ± 9.4461.7 ± 9.83
Sex: Female, Male
Sex: Female, Male(Participants)Combination TherapyRanibizumab MonotherapyLaser MonotherapyTotal
Female26332988
Male474243132
08

Study locations

20 sites
  • Calgary Retina Consultants
    Calgary, Alberta, Canada
  • UBC - Eye Care Center
    Vancouver, British Columbia, Canada
  • Retina Consultants of Victoria
    Victoria, British Columbia, Canada
  • Memorial University Health Sciences Centre / Bense Eye Centre
    St-John's, Newfoundland and Labrador, Canada
  • Victoria General Hospital, Department of Ophthalmology
    Halifax, Nova Scotia, Canada
  • Ivey Eye Institute
    London, Ontario, Canada
  • Canadian Centre for Advanced Eye Therapeutics
    Mississauga, Ontario, Canada
  • The Ottawa Hospital - General Campus
    Ottawa, Ontario, Canada
  • St-Michael's Hospital - Dept of Ophthalmology
    Toronto, Ontario, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario, Canada
  • Toronto Western Hospital
    Toronto, Ontario, Canada
  • Clinique ChirurgiVision
    Drummondville, Quebec, Canada
  • Hôpital Maisonneuve-Rosemont
    Montreal, Quebec, Canada
  • Hôpital Notre Dame (CHUM)
    Montreal, Quebec, Canada
  • Royal Victoria Hospital
    Montreal, Quebec, Canada
  • Centre Oculaire de Québec
    Québec, Quebec, Canada
  • Dr.Michel Giunta Clinique Médicale
    Sherbrooke, Quebec, Canada
  • Saskatoon City Hospital / Spadina Clinic
    Saskatoon, Saskatchewan, Canada
  • Institut de l'oeil des Laurentides
    Quebec, Canada
  • Memorial University Health Sciences Centre / Newfoundland Drive Medical Clinic
    St-John's, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2010
First posted
Jun 3, 2010
Start
Jul 2010
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Oct 23, 2014
Last update
Oct 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01135914
Responsible party
Sponsor
First posted
Jun 3, 2010
Start date
Jul 2010
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Oct 23, 2014
Last update
Oct 23, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion